SLC12A5 — Solute Carrier Family 12 Member 5 (KCC2)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC12A5 — Solute Carrier Family 12 Member 5 (KCC2)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC12A5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 12 Member 5 (K⁺/Cl⁻ Cotransporter 2, KCC2)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20q13.12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[57468](https://www.ncbi.nlm.nih.gov/gene/57468)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607707](https://www.omim.org/entry/607707)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000124140</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9NPJ9](https://www.uniprot.org/uniprot/Q9NPJ9)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Epilepsy, Hyperekplexia, Autism Spectrum Disorder, Schizophrenia, Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Developmental Stage</td>
<td>Primary Transporter</td>
</tr>
<tr>
<td class="label">Embryonic/Early Postnatal</td>
<td>NKCC1</td>
</tr>
<tr>
<td class="label">Postnatal Day 14+</td>
<td>KCC2</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CLP257/CLP290</td>
<td>KCC2 activator</td>
</tr>
<tr>
<td class="label">Daphnetin</td>
<td>KCC2 restoration</td>
</tr>
<tr>
<td class="label">VU0463271</td>
<td>KCC2 positive allosteric modulator</td>
</tr>
</table>
{{.infobox .infobox-gene}}
Overview
The SLC12A5 gene encodes the potassium-chloride cotransporter 2 (KCC2), a neuron-specific ion transporter essential for maintaining chloride homeostasis in the mature brain. KCC2 is a critical determinant of the polarity of GABAergic signaling, as it establishes the low intracellular chloride concentration required for hyperpolarizing GABA-A receptor responses.
KCC2 is expressed almost exclusively in neurons, particularly in hippocampal pyramidal neurons, cortical pyramidal cells, cerebellar Purkinje cells, and spinal cord motor neurons. Its expression is developmentally regulated, with a dramatic increase during the first two weeks of postnatal development in rodents (corresponding to early childhood in humans) that parallels the maturation of inhibitory circuits.
Structure and Function
Protein Structure
KCC2 is a member of the cation-chloride cotransporter (CCC) family, which includes:
- NKCC1 (SLC12A2): Na⁺/K⁺/2Cl⁻ cotransporter 1
- NKCC2 (SLC12A1): Na⁺/K⁺/2Cl⁻ cotransporter 2
- KCC1 (SLC12A4): K⁺/Cl⁻ cotransporter 1
- KCC2 (SLC12A5): K⁺/Cl⁻ cotransporter 2
- KCC3 (SLC12A6): K⁺/Cl⁻ cotransporter 3
- KCC4 (SLC12A7): K⁺/Cl⁻ cotransporter 4
The protein contains 12 transmembrane domains with intracellular N- and C-termini. It forms homomeric complexes that function as active transporters.
Transport Mechanism
KCC2 operates as an electroneutral symporter:
- Stoichiometry: 1 K⁺ + 1 Cl⁻ exported per cycle
- No net charge movement
- Driven by the K⁻ gradient (K⁺ flows downhill)
This establishes the chloride gradient where [Cl⁻]ᵢ ≈ 10-20 mM vs [Cl⁻]₀ ≈ 130 mM in mature neurons.
Role in Neuronal Function
GABAergic Signaling
The primary function of KCC2 is to maintain chloride homeostasis for proper GABAergic inhibition:
Mermaid diagram (expand to render)
In the mature brain, GABA binding opens GABA-A receptor channels, allowing chloride to flow IN, hyperpolarizing the neuron and inhibiting firing. In the developing brain or in disease states with impaired KCC2, the chloride gradient is reduced or reversed, making GABA excitatory.
Developmental Switch
During neuronal development, there is a transition from NKCC1-dominant to KCC2-dominant chloride extrusion:
This "developmental switch" is critical for proper circuit maturation [@rivoll].
Network Stability
KCC2 contributes to network stability through:
- Preventing hyperexcitability
- Supporting gamma oscillations (30-80 Hz)
- Regulating neuronal gain
- Preventing pathological burst firing
KCC2 in Neurodegenerative Diseases
Alzheimer's Disease
KCC2 dysfunction has been implicated in Alzheimer's disease pathogenesis:
- Aβ exposure reduces KCC2 expression and function
- Loss of KCC2 contributes to neuronal hyperexcitability
- Restoring KCC2 improves cognitive function (see [Daphnetin and KCC2 Restoration](/mechanisms/daphnetin-kcc2-alzheimers))
Epilepsy
KCC2 dysfunction is both cause and consequence of epileptic activity:
- Reduced KCC2 expression in epileptic tissue
- Contributing to seizure genesis
- Therapeutic targeting of KCC2 being investigated [@umetani]
Autism Spectrum Disorder
- Reduced KCC2 expression in ASD models
- Links to altered E/I balance
- Associated with social and cognitive deficits
Schizophrenia
- Decreased KCC2 in prefrontal cortex
- Contributes to working memory deficits
- Altered GABAergic signaling
Therapeutic Targeting
Pharmacological Activation
KCC2 represents a promising therapeutic target for multiple neurological conditions:
Rationale
Restoring KCC2 function can:
- Normalize E/I balance
- Reduce hyperexcitability
- Protect against excitotoxicity
- Improve cognitive function
References
[NCBI Gene: SLC12A5](https://www.ncbi.nlm.nih.gov/gene/57468)
[UniProt: KCC2_HUMAN (Q9NPJ9)](https://www.uniprot.org/uniprot/Q9NPJ9)
[Rivera et al., The K⁺/Cl⁻ cotransporter KCC2 renders GABA hyperpolarizing during neuronal maturation (1999)](https://doi.org/10.1038/35019)
[Umerani et al., The KCC2 chloride transporter is a drug target for refractory neurological disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38449480/)
[Kahle et al., Modulation of neuronal excitability by foreign ions and by disease-causing mutants of KCC2 (2008)](https://pubmed.ncbi.nlm.nih.gov/18614021/)
[Medina et al., Therapeutic targeting of KCC2 in disorders of diminished GABAergic signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/25004237/)See Also
- [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — causes
- [Apoptosis Pathway in Neurodegeneration](/wiki/mechanisms-apoptosis) — expressed_in
- [Apoptosis Pathway in Neurodegeneration](/wiki/mechanisms-apoptosis) — therapeutic_target
- [Cortical Layer-Specific Astrocytes](/wiki/cell-types-cortical-layer-astrocytes) — causes
- [Cortical Layer-Specific Astrocytes](/wiki/cell-types-cortical-layer-astrocytes) — expressed_in
- [Cortical Layer-Specific Astrocytes](/wiki/cell-types-cortical-layer-astrocytes) — therapeutic_target
- [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — causes
Pathway Diagram
The following diagram shows the key molecular relationships involving SLC12A5 — Solute Carrier Family 12 Member 5 (KCC2) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)